Emtricitabine

General adverse effects and adverse reactions

The most common adverse events during the use of regimens containing emtricitabine in combination with tenofovir and efavirenz were dizziness (8%), nausea (8–9%), diarrhea (7–8%), fatigue (7–8%), depression (4–7%), headache (5%), rash (5%), insomnia (4–5%), and hyperpigmentation (3%). Common laboratory abnormalities included raised amylase ≥ 132 U/l (17–18%), raised triglycerides ≥ 4.5 mmol/l (13–15%), raised creatine kinase ≥ 499 U/l in men and ≥ 424 U/l in women (12–17%), neutropenia <1.0 × 10 ⁹ /l (7%), hematuria (8–9%), and raised alanine aminotransferase activity ≥ 109 U/l (8%) [ , ].